<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Press Release Archives - Rigicon</title>
	<atom:link href="https://www.rigicon.us/category/press-release/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.rigicon.us/category/press-release/</link>
	<description>Innovative Urological Solutions</description>
	<lastBuildDate>Mon, 29 Sep 2025 10:56:34 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.1</generator>
	<item>
		<title>In-Depth Analysis Highlights Testi10™ Testicular Prosthesis Safety Outcomes</title>
		<link>https://www.rigicon.us/in-depth-analysis-highlights-testi10-testicular-prosthesis-safety-outcomes/</link>
		
		<dc:creator><![CDATA[Rigicon, Inc.]]></dc:creator>
		<pubDate>Wed, 29 May 2024 07:41:47 +0000</pubDate>
				<category><![CDATA[Press Release]]></category>
		<guid isPermaLink="false">https://www.rigicon.us/?p=8175</guid>

					<description><![CDATA[<p>Rigicon proudly announces the publication of a clinical study article titled &#8220;Short-term revision rate of Rigicon Testi10™ testicular prosthesis in adolescents and adults: a retrospective chart review&#8221; in the International Journal of Impotence Research. The study evaluated the safety and reliability of Rigicon&#8217;s Testi10™ in 427 patients, including 382 adults and 45 adolescents, who underwent [&#8230;]</p>
<p>The post <a href="https://www.rigicon.us/in-depth-analysis-highlights-testi10-testicular-prosthesis-safety-outcomes/">In-Depth Analysis Highlights Testi10™ Testicular Prosthesis Safety Outcomes</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Rigicon proudly announces the publication of a clinical study article titled &#8220;Short-term revision rate of Rigicon Testi10™ testicular prosthesis in adolescents and adults: a retrospective chart review&#8221; in the International Journal of Impotence Research.</p>
<p>The study evaluated the safety and reliability of Rigicon&#8217;s Testi10™ in 427 patients, including 382 adults and 45 adolescents, who underwent implantation between February 2019 and August 2023 by 132 physicians from 45 centers in 26 countries.</p>
<p>The Kaplan-Meier calculation of survival from removal or revision was an impressive 99.8% for all patients at 54 months of follow-up.</p>
<p>The study highlights the generally safe nature of testicular prosthesis implantation and the very rare incidence of revision surgery required for Rigicon Testi10™.</p>
<p>Testicular prosthesis implantation is a valuable solution for the physical, cosmetic, and psychological challenges associated with testicular loss, which can affect males of any age due to conditions such as congenital issues, undescended testes, tumors, torsion, infection, or trauma.</p>
<p>With this publication, Rigicon reinforces its commitment to innovation and improving the quality of life for patients through the development of advanced prosthetic urology solutions backed by clinical research.</p>
<p><strong>About Testicular Prosthesis </strong></p>
<p>A testicular prosthesis is a medical device used to simulate the appearance and feel of one or both testicles after they have been surgically removed due to conditions such as cancer, trauma, or congenital anomalies.</p>
<p>This device is an option when non-surgical treatments or the use of externally worn prosthetics are not desirable or effective.</p>
<p>The testicular prosthesis is designed to replicate the weight, shape, and texture of a natural testicle, enhancing cosmetic appearance and psychological well-being. It is typically made from silicone, which is inert and biocompatible, minimizing the risk of rejection or allergic reactions.</p>
<p>The testicular prosthesis is considered a safe and effective option for patients seeking to restore the appearance of their testicles after surgery. It is the preferred method for addressing the aesthetic concerns related to an empty scrotum and can be customized to match the size and firmness of the remaining natural testicle if present.</p>
<p><strong>About Rigicon</strong></p>
<p>Rigicon specializes in the research, development, and manufacturing of innovative prosthetic urology solutions, with 30 years of experience in urology. Rigicon continues to introduce cutting-edge technologies that improve patient outcomes and enhance the quality of life for those suffering from urinary conditions, including erectile dysfunction and urinary incontinence. Rigicon’s commitment to innovation and patient care continues to redefine industry standards and improve the quality of life for patients globally.</p>
<p>The post <a href="https://www.rigicon.us/in-depth-analysis-highlights-testi10-testicular-prosthesis-safety-outcomes/">In-Depth Analysis Highlights Testi10™ Testicular Prosthesis Safety Outcomes</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>New Study Confirms First Safety Outcomes of ContiReflex® Artificial Urinary Sphincter for Treating Male Incontinence</title>
		<link>https://www.rigicon.us/new-study-confirms-first-safety-outcomes-of-contireflex-artificial-urinary-sphincter-for-treating-male-incontinence/</link>
		
		<dc:creator><![CDATA[Sercan Ataikiz]]></dc:creator>
		<pubDate>Sun, 12 May 2024 12:37:08 +0000</pubDate>
				<category><![CDATA[Press Release]]></category>
		<guid isPermaLink="false">https://www.rigicon.us/?p=8170</guid>

					<description><![CDATA[<p>Rigicon proudly announces the publication of the clinical study article titled “First Safety Outcomes of ContiReflex® Artificial Urinary Sphincter for Treating Male Incontinence”. ContiReflex® has been shown to offer comparable safety outcomes to other devices on the market. Spanning from April 2022 to October 2023, the study involved the first 50 patients who received the [&#8230;]</p>
<p>The post <a href="https://www.rigicon.us/new-study-confirms-first-safety-outcomes-of-contireflex-artificial-urinary-sphincter-for-treating-male-incontinence/">New Study Confirms First Safety Outcomes of ContiReflex&lt;sup&gt;®&lt;/sup&gt; Artificial Urinary Sphincter for Treating Male Incontinence</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Rigicon proudly announces the publication of the clinical study article titled “First Safety Outcomes of ContiReflex<sup>® </sup>Artificial Urinary Sphincter for Treating Male Incontinence”.</p>
<p>ContiReflex<sup>®</sup> has been shown to offer comparable safety outcomes to other devices on the market.</p>
<p>Spanning from April 2022 to October 2023, the study involved the first 50 patients who received the ContiReflex<sup>®</sup> device. Most patients had undergone radical prostatectomy, with ages ranging from 57 to 84 years.</p>
<p>ContiReflex<sup>®</sup> showcased a high level of safety and operational reliability, evidenced by a 98% survival rate at 18 months post-implantation. Notably, the device required minimal surgical revisions, emphasizing its precision and effectiveness in clinical application.</p>
<p><em>Data on the “Early Safety Outcomes of the ContiReflex<sup>® </sup>Artificial Urinary Sphincter for Treating Male Incontinence” were presented at the 2024 American Urological Association Annual Meeting in San Antonio, Texas, USA.</em></p>
<p>ContiReflex<sup>®</sup> Enhanced Artificial Urinary Sphincter (AUS), a novel device developed by Rigicon, is being used to treat urinary incontinence due to intrinsic sphincter deficiency in cases such as incontinence following prostate surgery.</p>
<p>Unlike traditional devices, the ContiReflex<sup>®</sup> with its smart reflex balloon constantly senses intra-abdominal pressure changes and simultaneously adapts the pressure on the urethra, potentially helping patients stay dry more consistently.</p>
<p>The ContiReflex’s unique two-component design allows the system to adjust cuff pressure in real time, based on intra-abdominal pressure changes. This means that it can potentially achieve satisfactory continence outcomes with a lower baseline pressure than traditional devices.</p>
<p>New cuff sizes provide surgeons with a range of occlusive cuff options, which are available in incremental sizes of 0.25 cm, ranging from 3.5 to 5 cm, for a personalized fit to the patient’s urethral anatomy.</p>
<p>Unlike other devices on the market, ContiReflex<sup>®</sup> is uniquely manufactured with a HydroShield™ hydrophilic coating on all external surfaces, including the pressure-regulating balloon. The HydroShield™ coating allows for diverse dipping options, enabling a customized approach to meet the specific needs of the surgeon and the patient.</p>
<p><strong>About Urinary Incontinence</strong></p>
<p>Urinary incontinence (UI) is the involuntary loss of urine. Patients suffering from urinary incontinence are unable to control the release of urine from the bladder. While Stress Urinary Incontinence (SUI) is the most common type, there are different types of urinary incontinence. Stress urinary incontinence is the unexpected leakage of urine when an outside pressure occurs with activities such as heavy lifting, coughing, sneezing, laughing, or exercise. This outside pressure causes the already weakened bladder to leak urine.</p>
<p>Weakened urinary sphincters may be caused by: Surgery in the pelvic area or the prostate, injury to the urethra, medicines, being overweight, changes with age, and other causes. Urinary incontinence is a significant problem, affecting tens of millions of patients. UI is estimated to affect 1 out of 10 males, with increasing prevalence associated with aging.</p>
<p>Men with urinary incontinence have a higher rate of depression and are more likely to decrease participation in activities (e.g., decrease work hours, change employment, or take voluntary early retirement).</p>
<p><strong>About Artificial Urinary Sphincter</strong></p>
<p>Artificial Urinary Sphincter (AUS) is a medical device specifically designed to treat urinary incontinence. An Artificial Urinary Sphincter is a surgical treatment option when non-surgical or behavioral treatment options fail.</p>
<p>AUS will mimic the role of a healthy urinary sphincter (the two muscles controlling the exit of urine from the bladder through the urethra) closing the urethra, and preventing urine leakage. The patient will squeeze a pump located in his scrotum to release the cuff over the urethra and void. The cuff will return to its closed state in about 2 minutes to prevent urine leakage after voiding.</p>
<p>The artificial urinary sphincter is widely regarded as the gold standard for the treatment of urinary incontinence.</p>
<p><strong>About Rigicon</strong></p>
<p>Rigicon specializes in the research, development, and manufacturing of innovative prosthetic urology solutions, with 30 years of experience in urology. Rigicon continues to introduce cutting-edge technologies that improve patient outcomes and enhance the quality of life for those suffering from urinary conditions, including erectile dysfunction and urinary incontinence. Rigicon&#8217;s commitment to innovation and patient care continues to redefine industry standards and improve the quality of life for patients globally.</p>
<p>The post <a href="https://www.rigicon.us/new-study-confirms-first-safety-outcomes-of-contireflex-artificial-urinary-sphincter-for-treating-male-incontinence/">New Study Confirms First Safety Outcomes of ContiReflex&lt;sup&gt;®&lt;/sup&gt; Artificial Urinary Sphincter for Treating Male Incontinence</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Comprehensive Study Highlights Rigi10TM Malleable Penile Prosthesis Safety Outcomes Implanted Worldwide</title>
		<link>https://www.rigicon.us/comprehensive-study-highlights-rigi10tm-malleable-penile-prosthesis-safety-outcomes-implanted-worldwide/</link>
		
		<dc:creator><![CDATA[Sercan Ataikiz]]></dc:creator>
		<pubDate>Thu, 09 Nov 2023 10:44:36 +0000</pubDate>
				<category><![CDATA[Press Release]]></category>
		<guid isPermaLink="false">https://www.rigicon.us/?p=8033</guid>

					<description><![CDATA[<p>The clinical study, titled &#8220;Safety Outcomes of the First Rigi10 Malleable Penile Prostheses Implanted Worldwide&#8221; provides a comprehensive evaluation of the safety of the Rigi10 Malleable Penile Prosthesis. This study underscores the device&#8217;s status as a reliable solution for patients seeking treatment for erectile dysfunction (ED). Conducted between March 2019 and December 2022, it encompassed [&#8230;]</p>
<p>The post <a href="https://www.rigicon.us/comprehensive-study-highlights-rigi10tm-malleable-penile-prosthesis-safety-outcomes-implanted-worldwide/">Comprehensive Study Highlights Rigi10&lt;sup&gt;TM&lt;/sup&gt; Malleable Penile Prosthesis Safety Outcomes Implanted Worldwide</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The clinical study, titled &#8220;Safety Outcomes of the First Rigi10 Malleable Penile Prostheses Implanted Worldwide&#8221; provides a comprehensive evaluation of the safety of the Rigi10 Malleable Penile Prosthesis.</p>
<p>This study underscores the device&#8217;s status as a reliable solution for patients seeking treatment for erectile dysfunction (ED). Conducted between March 2019 and December 2022, it encompassed the participation of 605 first-time patients who were implanted with the Rigi10 by 46 high-volume, experienced implanters in 15 countries.</p>
<p>Survival calculations were performed at 12 months, 24 months, and 36 months, yielding Kaplan-Meier statistical survival curves with survival rates of 98.8%, 98.9%, and 99.2%, respectively. The device offers an efficient solution for addressing ED while ensuring exceptional safety and patient contentment. In this study, Rigi10 MPP was successful in treating ED in 603 out of 606 patients (99.5%). The paucity of revision operations was remarkable.</p>
<p>Compared to its competitors, notable features of Rigi10 include the supple bending capacity of its rods, simplifying implantation through a smaller corporotomy, and the availability of extra widths of rods that facilitate precise penile girth attainment. Support for this is evident in the study, which indicates that the 12 mm cylinder size, not offered by competitive devices, was the second most used cylinder width.</p>
<p>Rigi10’s safety was convincingly demonstrated; according to the results, Rigi10 MPP had no mechanical malfunctions, and the risk of prosthesis erosion (0.17%), infection (0.33%), or patient dissatisfaction (0.49%) was quite low. Less than 1% of all implants required reoperation for any reason.</p>
<p>The Rigi10 MPP, introduced in 2019, is a sterile, trimmable, and single-use implant that consists of two rods available in two lengths and six different widths, along with extender tips. The rods have stainless-steel wires, which are quite flexible, improving concealability under the patient’s clothing. The Rigi10 provides the required rigidity, comfort, and discretion to patients with ED.</p>
<p>Rigicon remains dedicated to advancing the field of prosthetic urology and providing patients with a safe and effective option for addressing ED. This study underscores Rigicon&#8217;s unwavering commitment to these goals.</p>
<p><strong>About Erectile Dysfunction</strong></p>
<p>Erectile Dysfunction, or ED, is the inability to achieve or sustain an erection suitable for sexual intercourse. ED is a common sexual disorder and may have a permanent course, as some cannot have any erection for the remaining part of their lives. ED might have a profound impact on the quality of life and social relationships of the patient.</p>
<p>ED may be caused by various diseases and disorders, including heart disease, diabetes, pelvic area damage due to surgery, accidents, or radiation therapy, benign prostatic hyperplasia (BPH, a non-cancerous enlargement of the prostate tissue), disorders associated with low testosterone levels, Parkinson’s disease, and other neurological diseases.<strong> </strong></p>
<p><strong>About Malleable Penile Prosthesis</strong></p>
<p>A malleable penile prosthesis is a medical device that allows an impotent patient to achieve an erection. The malleable implant consists of two rods that are always hard but pliable. All components are concealed within the body and cannot be seen from the outside. The penile implant rods reside in the penis on either side. No tissue is removed to place the rods; the rods simply occupy spaces previously filled with blood when one was potent. The rods do not disrupt the flow of urine or ejaculate, and they do not alter the sensation of the penis.<strong> </strong></p>
<p><strong>About Rigicon</strong></p>
<p>Rigicon specializes in the research, development, and manufacturing of innovative prosthetic urology solutions, with 30 years of experience in urology. We focus on creating a comprehensive product portfolio for urologists around the world. Committed to improving the quality of life for patients, Rigicon focuses on providing cutting-edge treatments that address various urological conditions, including erectile dysfunction and urinary incontinence.</p>
<p>The post <a href="https://www.rigicon.us/comprehensive-study-highlights-rigi10tm-malleable-penile-prosthesis-safety-outcomes-implanted-worldwide/">Comprehensive Study Highlights Rigi10&lt;sup&gt;TM&lt;/sup&gt; Malleable Penile Prosthesis Safety Outcomes Implanted Worldwide</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Newly published clinical study article demonstrates “Survival From Revision Surgery for New Rigicon Infla10® Three-piece Inflatable Penile Prosthesis Is Comparable to Preceding Devices”</title>
		<link>https://www.rigicon.us/survival-from-revision-surgery-for-new-rigicon-infla10/</link>
		
		<dc:creator><![CDATA[Sercan Ataikiz]]></dc:creator>
		<pubDate>Sat, 02 Sep 2023 10:13:30 +0000</pubDate>
				<category><![CDATA[Press Release]]></category>
		<guid isPermaLink="false">https://www.rigicon.us/?p=7971</guid>

					<description><![CDATA[<p>A recent clinical study article published titled &#8220;Survival From Revision Surgery for New Rigicon Infla10 Three-piece Inflatable Penile Prosthesis Is Comparable to Preceding Devices.&#8221; This study highlights the safety and performance of the Rigicon Infla10 Inflatable Penile Prosthesis, showcasing its potential as an effective solution in prosthetic urology. In its initial 2 to 3 years of [&#8230;]</p>
<p>The post <a href="https://www.rigicon.us/survival-from-revision-surgery-for-new-rigicon-infla10/">Newly published clinical study article demonstrates “Survival From Revision Surgery for New Rigicon Infla10&lt;sup&gt;®&lt;/sup&gt; Three-piece Inflatable Penile Prosthesis Is Comparable to Preceding Devices”</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>A recent clinical study article published titled &#8220;Survival From Revision Surgery for New Rigicon Infla10 Three-piece Inflatable Penile Prosthesis Is Comparable to Preceding Devices.&#8221; This study highlights the safety and performance of the Rigicon Infla10 Inflatable Penile Prosthesis, showcasing its potential as an effective solution in prosthetic urology.</p>
<p>In its initial 2 to 3 years of availability, the Rigicon Infla10 Inflatable Penile Prosthesis has shown notable resilience against the need for revision, similar to well-established already in-market devices. Analyzing data from the first 535 patients who received the Rigicon Infla10 (between January 2019 and August 2022), the study emphasizes its safety record, mechanical stability, infection incidence, and patient satisfaction in comparison with other devices.</p>
<p>Key findings echo the preliminary research, underlining the Infla10&#8217;s impressive durability. Mechanical Stability: The Rigicon Infla10&#8217;s mechanical failure rate is comparable to other available devices, signifying its long-term effectiveness.</p>
<p>Another key finding showed that Rigicon Infla10&#8217;s infection rate is found to be very low, with only a single instance among the 535 patients under observation. The infection rate of the Infla10 three-piece IPP with 103 different implanting surgeons is well within expectations.</p>
<p>Renowned urologist Dr. Steven K. Wilson, a contributor to the study, notes, &#8220;The Rigicon Infla10 marks progress in prosthetic urology. The data reaffirms the company&#8217;s commitment to innovative prosthetic urology solutions, providing reliable options that make a positive impact on patients&#8217; lives.”</p>
<h2>About Erectile Dysfunction</h2>
<p>Erectile Dysfunction, or ED, is the inability to achieve or sustain an erection suitable for sexual intercourse. ED is a common male sexual disorder and may maintain a permanent course as some men cannot have any erection for the remaining part of their life. ED might have a deep impact on the quality of life and social relationships of the patient.</p>
<p>ED may be basically caused by various diseases and disorders including heart disease, diabetes, pelvic area damage due to surgery, accidents or radiation therapy, benign prostatic hyperplasia (BPH, which is non-cancerous enlargement of the prostate tissue), disorders associated with low testosterone levels, Parkinson’s disease, and other neurologic diseases.</p>
<h2>About Inflatable Penile Prosthesis</h2>
<p>About Inflatable Penile Prosthesis (Three–Piece Inflatable Penile Prosthesis)</p>
<p>Inflatable devices, the most common type of penile implant used, can be inflated to create an erection, and deflated at other times. Three-piece inflatable implants use a fluid-filled reservoir implanted under the abdominal wall, a pump and a release valve placed inside the scrotum, and two inflatable cylinders inside the penis. (Source: Mayo Clinic)</p>
<p>Penile implant surgery is considered a gold standard therapy for men with erectile dysfunction.</p>
<h2>About Rigicon</h2>
<p>Rigicon specializes in the research, development, and manufacturing of innovative prosthetic urology solutions with 30 years’ of experience in Urology. We focus on creating a comprehensive product portfolio for urologist(s) around the world. Committed to improving the quality of life for patients, Rigicon focuses on providing cutting-edge treatments that address various urological conditions, including erectile dysfunction and urinary incontinence.</p>
<p>The post <a href="https://www.rigicon.us/survival-from-revision-surgery-for-new-rigicon-infla10/">Newly published clinical study article demonstrates “Survival From Revision Surgery for New Rigicon Infla10&lt;sup&gt;®&lt;/sup&gt; Three-piece Inflatable Penile Prosthesis Is Comparable to Preceding Devices”</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>New Study Confirms First Safety Outcomes for Rigicon ContiClassic®: Artificial Urinary Sphincter, in Male Stress Urinary Incontinence Treatment</title>
		<link>https://www.rigicon.us/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic/</link>
		
		<dc:creator><![CDATA[Sercan Ataikiz]]></dc:creator>
		<pubDate>Wed, 23 Aug 2023 10:29:54 +0000</pubDate>
				<category><![CDATA[Press Release]]></category>
		<guid isPermaLink="false">https://www.rigicon.us/?p=7965</guid>

					<description><![CDATA[<p>We proudly announce the publication of the clinical study article &#8220;First Safety Outcomes for Rigicon ContiClassic: Artificial Urinary Sphincter.&#8221; This study sheds light on the safety profile of the Rigicon ContiClassic in treating male stress urinary incontinence (SUI) and positions it as a comparable, innovative option alongside existing solutions. Introduced to the international market just two [&#8230;]</p>
<p>The post <a href="https://www.rigicon.us/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic/">New Study Confirms First Safety Outcomes for Rigicon ContiClassic&lt;sup&gt;®&lt;/sup&gt;: Artificial Urinary Sphincter, in Male Stress Urinary Incontinence Treatment</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>We proudly announce the publication of the clinical study article &#8220;First Safety Outcomes for Rigicon ContiClassic: Artificial Urinary Sphincter.&#8221; This study sheds light on the safety profile of the Rigicon ContiClassic in treating male stress urinary incontinence (SUI) and positions it as a comparable, innovative option alongside existing solutions.</p>
<p>Introduced to the international market just two years ago, the Rigicon ContiClassic<sup> </sup>Artificial Urinary Sphincter has rapidly garnered attention as a viable treatment option for men grappling with stress urinary incontinence.</p>
<p>The study focused on patient demographics, surgical intricacies, and underlying causes of incontinence, revealing commendable efficacy across a diverse patient cohort. Notably, participants had a mean age of 68.3 years, with post-radical prostatectomy-related urinary incontinence accounting for 58.6% of implantations. Encouragingly, the study reported no instances of infections or significant complications. A highlight of the study was the Kaplan-Meier calculation, demonstrating an impressive 93.2% survival rate at the 12-month milestone.</p>
<p>Renowned urology authority, Dr. Steven K. Wilson, commended the study&#8217;s findings, stating, &#8220;The Rigicon ContiClassic represents an important step in addressing male stress urinary incontinence. Its innovative design and comparable safety outcomes position it as a valuable choice for patients seeking effective solutions.&#8221;</p>
<p><strong>About Urinary Incontinence</strong></p>
<p>Urinary incontinence (UI) is the involuntary loss of urine. Patients suffering from Urinary incontinence are unable to control the release of urine from the bladder. While Stress Urinary Incontinence is the most common type, there are different types of urinary incontinence. Stress urinary incontinence is the unexpected leakage of urine when an outside pressure occurs with activities such as heavy lifting, coughing, sneezing, laughing, or exercise. This outside pressure causes the already weakened bladder to leak urine.</p>
<p>Weakened urinary sphincters may be caused by: Surgery in the pelvic area or the prostate, injury to the urethra, medicines, being overweight, changes with age, and other causes. Urinary incontinence is a significant problem, affecting tens of millions of patients. UI is estimated to affect 1 out of 10 males, with increasing prevalence associated with aging.</p>
<p>Men with Urinary Incontinence have a higher rate of depression and are more likely to decrease participation in activities (e.g., decrease work hours, change employment, or take voluntary early retirement).</p>
<p>Most patients who experience weekly urinary incontinence do not seek care for it. Many who sought treatment believe that none was provided and many who received treatment continue to have troubling symptoms.</p>
<p>&nbsp;</p>
<p><strong>About Artificial Urinary Sphincter</strong></p>
<p>Artificial Urinary Sphincter (AUS) is a medical device specifically designed to treat urinary incontinence. Artificial Urinary Sphincter is a surgical treatment option when non-surgical or behavioral treatment options fail.</p>
<p>AUS will mimic the role of a healthy urinary sphincter (the two muscles controlling the exit of urine from the bladder through the urethra) AUS will close the urethra preventing urine leakage. The patient will squeeze a pump located in his scrotum to release the cuff over the urethra and void. The cuff will return to its closed state in around 2 minutes to prevent urine leakage after voiding.<br />
The artificial urinary sphincter is widely regarded as the gold standard for the treatment of Urinary Incontinence.</p>
<p><strong>About Rigicon </strong></p>
<p>Rigicon specializes in the research, development, and manufacturing of innovative prosthetic urology solutions with 30 years’ experience in Urology. We focus on creating a comprehensive product portfolio for urologist(s) around the world. Committed to improving the quality of life for patients, Rigicon focuses on providing cutting-edge treatments that address various urological conditions, including erectile dysfunction and urinary incontinence.</p>
<p>The post <a href="https://www.rigicon.us/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic/">New Study Confirms First Safety Outcomes for Rigicon ContiClassic&lt;sup&gt;®&lt;/sup&gt;: Artificial Urinary Sphincter, in Male Stress Urinary Incontinence Treatment</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Rigicon® proudly announces the launch of the HL-LEVINE Combo Prosthesis Tool</title>
		<link>https://www.rigicon.us/rigicon-proudly-announces-the-launch-of-the-hl-levine-combo-prosthesis-tool/</link>
		
		<dc:creator><![CDATA[Rigicon, Inc.]]></dc:creator>
		<pubDate>Fri, 16 Jun 2023 00:06:36 +0000</pubDate>
				<category><![CDATA[Press Release]]></category>
		<guid isPermaLink="false">https://www.rigicon.us/?p=7809</guid>

					<description><![CDATA[<p>The new HL-LEVINE Combo Prosthesis Tool represents Rigicon’s commitment to innovation via collaboration with global physician partners.  Dr. Huseyin Luleci and Dr. Laurence Levine, both world-renowned prosthetic urology surgeons, worked together to create this innovative combination surgical tool.  The surgical tool is a combination HL dilator tool and the traditional Furlow instrument both used for [&#8230;]</p>
<p>The post <a href="https://www.rigicon.us/rigicon-proudly-announces-the-launch-of-the-hl-levine-combo-prosthesis-tool/">Rigicon&lt;sup&gt;®&lt;/sup&gt; proudly announces the launch of the HL-LEVINE Combo Prosthesis Tool</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The new HL-LEVINE Combo Prosthesis Tool represents Rigicon’s commitment to innovation via collaboration with global physician partners.  Dr. Huseyin Luleci and Dr. Laurence Levine, both world-renowned prosthetic urology surgeons, worked together to create this innovative combination surgical tool.  The surgical tool is a combination HL dilator tool and the traditional Furlow instrument both used for penile implant surgery. This new tool was designed to help facilitate better patient outcomes by decreasing operating time and eliminating the need to switch between the Furlow and HL dilator during the implant procedure.</p>
<p>&#8220;By merging these two key devices, the HL-LEVINE Combo Prosthesis Tool brings enhanced efficiency and simplicity to urological surgery,&#8221; said Dr Luleci. &#8220;This is an important leap forward in making complex procedures more manageable and, importantly, reducing the patient&#8217;s time in the operating room.&#8221;</p>
<p>According to Dr. Levine “the HL-Levine Combo Prosthesis Tool facilitates easier dilation and penile implant insertion, helping to minimize potential surgical complications and promote better postoperative outcomes. By leveraging the design features of the two individual tools, the HL-LEVINE Combo Prosthesis Tool provides an innovative new option for surgeons to utilize during implant procedures.</p>
<p><strong>About Erectile Dysfunction</strong></p>
<p>Erectile Dysfunction, or ED, is the inability to achieve or sustain an erection suitable for sexual intercourse. ED is a common male sexual disorder and may maintain a permanent course as some men cannot have any erection for the remaining part of their life. ED might have a deep impact on the quality of life and social relationships of the patient.</p>
<p>ED may be basically caused by various diseases and disorders including heart disease, diabetes, pelvic area damage due to surgery, accidents or radiation therapy, benign prostatic hyperplasia (BPH, which is non-cancerous enlargement of the prostate tissue), disorders associated with low testosterone levels, Parkinson’s disease, and other neurologic diseases.</p>
<p><strong>About Inflatable Penile Prosthesis (Three Piece Inflatable Penile Prosthesis)</strong></p>
<p>Inflatable devices, the most common type of penile implants used, can be inflated to create an erection, and deflated at other times. Three-piece inflatable implants use a fluid-filled reservoir implanted under the abdominal wall, a pump and a release valve placed inside the scrotum, and two inflatable cylinders inside the penis. (Source: Mayo Clinic)</p>
<p>Penile implant surgery is considered a gold standard therapy for men with erectile dysfunction.</p>
<p><strong>About Rigicon</strong></p>
<p>Rigicon specializes in the research, development, and manufacturing of innovative urological solutions with 30 years’ of experience in Prosthetic Urology. We focus on creating a comprehensive product portfolio for urologist(s) around the world. Committed to improving the quality of life for patients, Rigicon focuses on providing cutting-edge treatments that address various urological conditions, including erectile dysfunction and urinary incontinence.</p>
<p>The post <a href="https://www.rigicon.us/rigicon-proudly-announces-the-launch-of-the-hl-levine-combo-prosthesis-tool/">Rigicon&lt;sup&gt;®&lt;/sup&gt; proudly announces the launch of the HL-LEVINE Combo Prosthesis Tool</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>New Study Confirms Safety and High Satisfaction Rates of Rigicon Infla10® Three-Piece Inflatable Penile Prosthesis for Erectile Dysfunction Treatment</title>
		<link>https://www.rigicon.us/new-study-confirms-safety-and-high-satisfaction-rates-of-rigicon-infla10-three-piece-inflatable-penile-prosthesis-for-erectile-dysfunction-treatment/</link>
		
		<dc:creator><![CDATA[Rigicon, Inc.]]></dc:creator>
		<pubDate>Mon, 08 May 2023 08:02:11 +0000</pubDate>
				<category><![CDATA[Press Release]]></category>
		<guid isPermaLink="false">https://www.rigicon.us/?p=7798</guid>

					<description><![CDATA[<p>A recent study conducted by esteemed prosthetic urology implanters Steven K. Wilson (CA, USA), Mariano Rossello (Spain), Pedro Maria (NY, USA), and Lexiaochuan Wen (MA, USA) has shown promising safety outcomes and high patient satisfaction rates for the Infla10 Three-Piece Inflatable Penile Prosthesis (Rigicon, New York) as a treatment option for patients with erectile dysfunction who [&#8230;]</p>
<p>The post <a href="https://www.rigicon.us/new-study-confirms-safety-and-high-satisfaction-rates-of-rigicon-infla10-three-piece-inflatable-penile-prosthesis-for-erectile-dysfunction-treatment/">New Study Confirms Safety and High Satisfaction Rates of Rigicon Infla10&lt;sup&gt;®&lt;/sup&gt; Three-Piece Inflatable Penile Prosthesis for Erectile Dysfunction Treatment</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>A recent study conducted by esteemed prosthetic urology implanters Steven K. Wilson (CA, USA), Mariano Rossello (Spain), Pedro Maria (NY, USA), and Lexiaochuan Wen (MA, USA) has shown promising safety outcomes and high patient satisfaction rates for the Infla10 Three-Piece Inflatable Penile Prosthesis (Rigicon, New York) as a treatment option for patients with erectile dysfunction who have not responded to conservative therapies or prefer a definitive solution.</p>
<p>The study included 535 patients who underwent Infla10 implantation between June 2019 and April 2022, with 103 surgeons from 26 centers participating. Patients were followed up to evaluate the safety of the device, with factors such as revision/explantation, reoperation for infection, mechanical failure, and medical reasons being recorded. Statistical analysis was performed using SPSS 25.0 (IBM, US) and Kaplan Meier survival statistics.</p>
<p>The Infla10 Three-Piece Inflatable Penile Prosthesis features a new-generation hydrophilic coating on all external surfaces, including the reservoir, which allows for compatibility with various antibiotics tailored to the patient’s needs. This innovative design has contributed to the positive results observed in the study.</p>
<p>These findings further demonstrate the safety and effectiveness of the Infla10 Three-Piece Inflatable Penile Prosthesis, solidifying its position as a reliable treatment option for patients with erectile dysfunction.</p>
<h3>About Erectile Dysfunction</h3>
<p>Erectile Dysfunction, or ED, is the inability to achieve or sustain an erection suitable for sexual intercourse. ED is actually a common male sexual disorder and may maintain a permanent course as some men cannot have any erection for the remaining part of their life. ED might have a deep impact on the quality of life and social relationships of the patient.</p>
<p>ED may be basically caused by various diseases and disorders including heart disease, diabetes, pelvic area damage due to surgery, accidents or radiation therapy, benign prostatic hyperplasia (BPH, which is non-cancerous enlargement of the prostate tissue), disorders associated with low testosterone levels, Parkinson’s disease, and other neurologic diseases.</p>
<p>About Inflatable Penile Prosthesis (Three–Piece Inflatable Penile Prosthesis)</p>
<p>Inflatable devices, the most common type of penile implant used, can be inflated to create an erection, and deflated at other times. Three-piece inflatable implants use a fluid-filled reservoir implanted under the abdominal wall, a pump and a release valve placed inside the scrotum, and two inflatable cylinders inside the penis. (Source: Mayo Clinic)</p>
<p>Penile implant surgery is considered a gold standard therapy for men with erectile dysfunction.</p>
<h3>About Rigicon</h3>
<p>Rigicon specializes in the research, development, and manufacturing of innovative urological solutions with 30 years experience on Urology. We focus on creating a comprehensive product portfolio for urologist(s) around the world. Committed to improving the quality of life for patients, Rigicon focuses on providing cutting-edge treatments that address various urological conditions, including erectile dysfunction and urinary incontinence.</p>
<p>The post <a href="https://www.rigicon.us/new-study-confirms-safety-and-high-satisfaction-rates-of-rigicon-infla10-three-piece-inflatable-penile-prosthesis-for-erectile-dysfunction-treatment/">New Study Confirms Safety and High Satisfaction Rates of Rigicon Infla10&lt;sup&gt;®&lt;/sup&gt; Three-Piece Inflatable Penile Prosthesis for Erectile Dysfunction Treatment</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Rigicon®  Launches the Conti®  Artificial Urinary Sphincter Systems: ContiClassic® Artificial Urinary Sphincter and ContiReflex®  Artificial Urinary Sphincter</title>
		<link>https://www.rigicon.us/rigicon-launches-the-conti-artificial-urinary-sphincter-systems/</link>
		
		<dc:creator><![CDATA[Rigicon, Inc.]]></dc:creator>
		<pubDate>Wed, 06 May 2020 06:51:40 +0000</pubDate>
				<category><![CDATA[Press Release]]></category>
		<guid isPermaLink="false">https://www.rigicon.us/?p=2407</guid>

					<description><![CDATA[<p>Rigicon is globally launching two new artificial urinary sphincter models: ContiClassic Artificial Urinary Sphincter and ContiReflex Artificial Urinary Sphincter. Rigicon announces that the ContiClassic Artificial Urinary Sphincter and the ContiReflex Artificial Urinary Sphincter models have recently received CE Mark Approval and are initially available in all major European markets. ContiClassic Artificial Urinary Sphincter and ContiReflex [&#8230;]</p>
<p>The post <a href="https://www.rigicon.us/rigicon-launches-the-conti-artificial-urinary-sphincter-systems/">Rigicon&lt;sup&gt;®&lt;/sup&gt;  Launches the Conti&lt;sup&gt;®&lt;/sup&gt;  Artificial Urinary Sphincter Systems: ContiClassic&lt;sup&gt;®&lt;/sup&gt; Artificial Urinary Sphincter and ContiReflex&lt;sup&gt;®&lt;/sup&gt;  Artificial Urinary Sphincter</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Rigicon is globally launching two new artificial urinary sphincter models: ContiClassic Artificial Urinary Sphincter and ContiReflex Artificial Urinary Sphincter. Rigicon announces that the ContiClassic Artificial Urinary Sphincter and the ContiReflex Artificial Urinary Sphincter models have recently received CE Mark Approval and are initially available in all major European markets.<span id="more-2407"></span></p>
<p>ContiClassic Artificial Urinary Sphincter and ContiReflex Artificial Urinary Sphincter are implant devices that treat Urinary Incontinence (UI). Conti Artificial Urinary Sphincter Systems are indicated to treat urinary incontinence due to external urethral sphincter deficiency in cases such as incontinence following prostate surgery. Conti Artificial Urinary Sphincter Systems are designed to restore the function of the normal (healthy) urinary sphincter that restricts urine flow out of the bladder.</p>
<p>Conti Artificial Urinary Sphincter Systems offer unique features for the treatment of Urinary Incontinence. ContiReflex AUS offers sophisticated intra-abdominal pressure regulation via its innovative pressure-regulating balloon design.</p>
<p>Conti Artificial Urinary Sphincter Systems are designed to offer decisive solutions to physiological and mechanical problems faced with conventional AUS systems. Both AUS models are designed to reduce urethral erosion and device fluid loss, the two most common causes of treatment failure.</p>
<p>Conti Artificial Urinary Sphincter Systems are available in a wide and new range of cuff sizes to offer the best fit to the patient’s urethral anatomy. All components of the Conti Artificial Urinary Sphincter Systems are offered with the HydroShield™ hydrophilic coating, giving the physician freedom to choose the aqueous solution dip of choice.</p>
<p>Additionally, the innovative design of the EasyClick™ Y-connectors will facilitate tandem occlusive cuff placement. The global roll-out of Conti Artificial Urinary Sphincter Systems will continue throughout 2020. A multi-center clinical trial, “Evaluation of the Rigicon Conti Artificial Urinary Sphincter Systems for the Treatment of Patients with Urinary Incontinence (ERASE UI)”, is scheduled for 2020 Q4.</p>
<p><strong>About Urinary Incontinence</strong></p>
<p>Urinary incontinence (UI) is the involuntary loss of urine. Patients suffering from Urinary incontinence are unable to control the release of urine from the bladder. While Stress Urinary Incontinence is the most common type, there are different types of urinary incontinence. Stress urinary incontinence is the unexpected leakage of urine when an outside pressure occurs with activities such as heavy lifting, coughing, sneezing, laughing, or exercise. This outside pressure causes the already weakened bladder to leak urine.</p>
<p>Weakened urinary sphincters may be caused by:</p>
<p>• Surgery in the pelvic area or the prostate<br />
• Injury to the urethra<br />
• Medicines<br />
• Being overweight<br />
• Changes with age<br />
• Other causes</p>
<p>Urinary incontinence is a significant problem, affecting tens of millions of patients. UI is estimated to affect 1 out of 10 males, with increasing prevalence associated with aging.</p>
<p>Men with Urinary Incontinence have a higher rate of depression and are more likely to decrease participation in activities (e.g., decrease work hours, change employment, or take voluntary early retirement)<sup>1</sup></p>
<p>The majority of patients who experience weekly urinary incontinence do not seek care for it. Many who sought treatment believe that none was provided and many who received treatment continue to have troubling symptoms.<sup>2</sup></p>
<p><strong>About Artificial Urinary Sphincter</strong></p>
<p>Artificial Urinary Sphincter (AUS) is a medical device specifically designed to treat urinary incontinence.</p>
<p>Artificial Urinary Sphincter is a surgical treatment option when non-surgical or behavioral treatment options fail.</p>
<p>AUS will mimic the role of a healthy urinary sphincter (the two muscles controlling the exit of urine from the bladder through the urethra) AUS will close the urethra preventing urine leakage. The patient will squeeze a pump located in his scrotum to release the cuff over the urethra and void. The cuff will return to its closed state in around 2 minutes to prevent urine leakage after voiding.<br />
The artificial urinary sphincter is widely regarded as the gold standard for the treatment of Urinary Incontinence.</p>
<p><strong>About Rigicon</strong></p>
<p>Rigicon, Inc. designs and manufactures innovative urological implants with a keen focus on creating a comprehensive product portfolio and a commitment to delivering high-quality and innovative urology products for patients and physicians all over the world.</p>
<hr />
<p><strong>References</strong></p>
<p>1 &#8211; Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L., “Impact of overactive bladder symptoms on employment, social<br />
interactions and emotional well-being in six European countries” BJU International. 2006;97:96–100.<br />
2- Harris S.S., Link C.L., Tennstedt S.L., “Care seeking and treatment for urinary incontinence in a diverse<br />
population”, J Urol. 2007;177:680–684</p>
<p>The post <a href="https://www.rigicon.us/rigicon-launches-the-conti-artificial-urinary-sphincter-systems/">Rigicon&lt;sup&gt;®&lt;/sup&gt;  Launches the Conti&lt;sup&gt;®&lt;/sup&gt;  Artificial Urinary Sphincter Systems: ContiClassic&lt;sup&gt;®&lt;/sup&gt; Artificial Urinary Sphincter and ContiReflex&lt;sup&gt;®&lt;/sup&gt;  Artificial Urinary Sphincter</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Rigicon&#8217;s New Generation Malleable Penile Prosthesis Rigi10™ receives FDA clearance and the launch of the Innovative Inflatable Penile Prosthesis Infla10® in Europe, Asia Pacific and Latin America has been a great success</title>
		<link>https://www.rigicon.us/fda-clears-rigicon/</link>
		
		<dc:creator><![CDATA[Rigicon, Inc.]]></dc:creator>
		<pubDate>Thu, 05 Sep 2019 06:49:36 +0000</pubDate>
				<category><![CDATA[Press Release]]></category>
		<guid isPermaLink="false">https://www.rigicon.us/?p=2404</guid>

					<description><![CDATA[<p>Rigicon, Inc. announces that the U.S. Food and Drug Administration (FDA) has cleared Rigi10 Malleable Penile Prosthesis for implantation into the corpora cavernosa of the penis for men who are diagnosed with erectile dysfunction. The prosthesis is implanted to provide adequate penile rigidity for sexual intercourse. Rigi10 is easy to implant and easy to use. [&#8230;]</p>
<p>The post <a href="https://www.rigicon.us/fda-clears-rigicon/">Rigicon&#8217;s New Generation Malleable Penile Prosthesis Rigi10™ receives FDA clearance and the launch of the Innovative Inflatable Penile Prosthesis Infla10&lt;sup&gt;®&lt;/sup&gt; in Europe, Asia Pacific and Latin America has been a great success</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Rigicon, Inc. announces that the U.S. Food and Drug Administration (FDA) has cleared Rigi10 Malleable Penile Prosthesis for implantation into the corpora cavernosa of the penis for men who are diagnosed with erectile dysfunction. The prosthesis is implanted to provide adequate penile rigidity for sexual intercourse.<span id="more-2404"></span></p>
<p>Rigi10 is easy to implant and easy to use. The Flexible Rod Technology™ enables higher bending angles with no spring-backs. Rigi10 is offered in 5 different diameters and 2 sizes for a better fit to the patient’s anatomy.</p>
<p>Infla10 is the next-generation inflatable penile prosthesis designed with years of experience in urology. Infla10 incorporates a hydrophilic coating on all external component surfaces to facilitate rapid and strong absorption of the solution on the device and promote easier device implantation. The innovative Rapid-Pump™ mechanism offers greater ease and speed for patients when inflating and deflating the prosthesis. Infla10 AX version offers the patients anatomical girth and length expansion addressing concerns regarding post-operative penile shortening.</p>
<p>Penile Prosthesis is for treating erectile dysfunction, a condition affecting more than 200 million men annually worldwide, with nearly 50% of men over 60 suffering from moderate to severe symptoms.[1,2]</p>
<p><strong>About Erectile Dysfunction</strong></p>
<p>Erectile Dysfunction, or ED, is the inability to achieve or sustain an erection suitable for sexual intercourse. ED is actually a common male sexual disorder and may maintain a permanent course as some men cannot have any erection for the remaining part of their life. ED might have a deep impact on the quality of life and social relationships of the patient.</p>
<p>ED may be basically caused by various diseases and disorders including heart disease, diabetes, pelvic area damage due to surgery, accidents or radiation therapy, benign prostatic hyperplasia (BPH, which is non-cancerous enlargement of the prostate tissue), disorders associated with low testosterone levels, Parkinson’s disease, and other neurologic diseases.</p>
<p><strong>About Malleable Penile Prosthesis (Semi-Rigid Penile Prosthesis)</strong></p>
<p>A malleable penile prosthesis is a medical device that allows an impotent male to achieve an erection. The malleable implant consists of two rods that are always hard but pliable. All components are concealed within the body and cannot be seen from the outside. The penile implant cylinders reside in the penis on either side. No tissue is removed to place the rods; the rods simply occupy spaces that were previously filled with blood, when one was potent. The rods do not disrupt the flow of urine or ejaculate. The rods do not alter the sensation of the penis.</p>
<p><strong>About Inflatable Penile Prosthesis (Three-Piece Inflatable Penile Prosthesis)</strong></p>
<p>Inflatable devices, the most common type of penile implant used, can be inflated to create an erection and deflated at other times. Three-piece inflatable implants use a fluid-filled reservoir implanted under the abdominal wall, a pump and a release valve placed inside the scrotum, and two inflatable cylinders inside the penis. (Source: Mayo Clinic)</p>
<p>Penile implant surgery is considered a gold standard therapy for men with erectile dysfunction.</p>
<p><strong>About Rigicon</strong></p>
<p>Rigicon designs and manufactures innovative urological implants with 30 years of experience in Urology. We focus on creating a comprehensive product portfolio for urologist(s) around the world. Our commitment is to deliver high-quality and innovative urology products to our valued patients and physicians.</p>
<p>[1]US Census Bureau.</p>
<p>[2] Aytac IA et al (1996) &#8211; The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJUI, 84: 50-6.</p>
<p>The post <a href="https://www.rigicon.us/fda-clears-rigicon/">Rigicon&#8217;s New Generation Malleable Penile Prosthesis Rigi10™ receives FDA clearance and the launch of the Innovative Inflatable Penile Prosthesis Infla10&lt;sup&gt;®&lt;/sup&gt; in Europe, Asia Pacific and Latin America has been a great success</a> appeared first on <a href="https://www.rigicon.us">Rigicon</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
